Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of GLPG1690 in idiopathic pulmonary fibrosis
jRCT2031210008Phase 3Active, not recruiting
- Sponsor
- Galapagos NV
- Start
- Jan 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (3 arms), sponsored by Galapagos NV. Primary endpoint: Rate of decline of forced vital capacity (FVC) in mL. Started Jan 2021; status: active, not recruiting.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2031210008.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210008.